Eashaal Imtiaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eashaal Imtiaz has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Raghabendra Kumar Mahato
Gandaki Medical College Teaching Hospital and Research Center, Pokhara, Nepal
10 shared publications - Aiman Tahir
Department of Medicine, Azad Jammu and Kashmir Medical College, Muzaffarabad, AJK, Pakistan
6 shared publications - Fatima Zohra Ali
Department of Medicine, Ayub Medical College, Abbottabad, Pakistan
5 shared publications - Muhammad Shahmeer Khan
Department of Medicine, Ayub Medical College, Abbottabad, Pakistan
4 shared publications - Mustabshirah Jadoon
Ayub Medical College, Abbottabad, Pakistan
3 shared publications - Sana Soomro
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
3 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3872-3873
Molecular glue degraders versus PROTACs: a novel paradigm in targeted protein degradation
Many proteins that cause cancer are still out of reach for regular drugs because they do not have the right structure for small molecules to bind to. Targeted protein degradation (TPD) is a new way to do things. Instead of blocking these proteins, it takes over the cell’s own disposal system, the ubiquitin-proteasome system, to get rid of them completely. Two main strategies have emerged: molecular glue degraders, which are small compounds that help an E3 ligase find and tag a target protein, and PROteolysis TArgeting Chimeras (PROTACs), which are engineered bifunctional molecules that physically connect a target to a degradation pathway. Both have shown real promise in early clinical work. PROTACs that target Bruton’s tyrosine kinase have shown great response rates in B-cell cancers, and molecular glues that target Ikaros family proteins (IKZF1/3) are still helping people with blood cancers. But there are still problems. PROTACs have trouble dissolving and getting into the body through the mouth. The “hook effect” can make them less effective at higher doses, and both strategies rely heavily on a small number of E3 ligases. To make progress, we need to add more enzymes to our toolkit, design molecules better, and get better data from clinical trials. With cooperation from academia, industry, and regulators, TPD could significantly expand the druggable proteome and transform cancer treatment.
- 22 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3872-3873
Open AccessMolecular glue degraders versus PROTACs: a novel paradigm in targeted protein degradation
Many proteins that cause cancer are still out of reach for regular drugs because they do not have the right structure for small molecules to bind to. Targeted protein degradation (TPD) is a new way to do things. Instead of blocking these proteins, it takes over the cell’s own disposal system, the ubiquitin-proteasome system, to get rid of them completely. Two main strategies have emerged: molecular glue degraders, which are small compounds that help an E3 ligase find and tag a target protein, and PROteolysis TArgeting Chimeras (PROTACs), which are engineered bifunctional molecules that physically connect a target to a degradation pathway. Both have shown real promise in early clinical work. PROTACs that target Bruton’s tyrosine kinase have shown great response rates in B-cell cancers, and molecular glues that target Ikaros family proteins (IKZF1/3) are still helping people with blood cancers. But there are still problems. PROTACs have trouble dissolving and getting into the body through the mouth. The “hook effect” can make them less effective at higher doses, and both strategies rely heavily on a small number of E3 ligases. To make progress, we need to add more enzymes to our toolkit, design molecules better, and get better data from clinical trials. With cooperation from academia, industry, and regulators, TPD could significantly expand the druggable proteome and transform cancer treatment.
- Open Access
- 17 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3840-3841
Assessment of pembrolizumab in advanced endometrial carcinoma: a letter to the editor
- 17 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3840-3841
Open AccessAssessment of pembrolizumab in advanced endometrial carcinoma: a letter to the editor
- Open Access
- 21 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2216-2217
Incidentalomas of the heart: lipomatous hypertrophy of the interatrial septum in the GLP-1 era
- 21 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2216-2217
Open AccessIncidentalomas of the heart: lipomatous hypertrophy of the interatrial septum in the GLP-1 era
- Open Access
- 20 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2220-2221
Augmented reality (AR) rehabilitation for homonymous hemianopia: ‘prism-free’ field expansion via smart glasses
- 20 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2220-2221
Open AccessAugmented reality (AR) rehabilitation for homonymous hemianopia: ‘prism-free’ field expansion via smart glasses
- Open Access
- 20 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2224-2225
Short-chain fatty acids (SCFAs) and the “Regulatory” B-cell: why fiber diet may reduce relapse in IgA vasculitis
- 20 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2224-2225
Open AccessShort-chain fatty acids (SCFAs) and the “Regulatory” B-cell: why fiber diet may reduce relapse in IgA vasculitis
- Open Access
- 20 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2210-2211
The unforeseen consequence of smart bio-implants for hemophilia: chronic inflammation and antibody development
- 20 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2210-2211
Open AccessThe unforeseen consequence of smart bio-implants for hemophilia: chronic inflammation and antibody development
- Open Access
- 20 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2200-2201
Haptic-feedback robotics in transcervical fetal endoscopy: reducing uterine irritability and the risk of preterm labor
- 20 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2200-2201
Open AccessHaptic-feedback robotics in transcervical fetal endoscopy: reducing uterine irritability and the risk of preterm labor
- Open Access
- 9 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2206-2207
In-vivo CRISPR editing for ATTR-CM: therapeutic transthyretin silencing through hepatic genome correction
- 9 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2206-2207
Open AccessIn-vivo CRISPR editing for ATTR-CM: therapeutic transthyretin silencing through hepatic genome correction
- Open Access
- 16 December 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2138-2139
Patient-specific precision microbiome modulation: rethinking therapeutic strategies in IBD
- 16 December 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2138-2139
Open AccessPatient-specific precision microbiome modulation: rethinking therapeutic strategies in IBD
- Open Access
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 1096-1097
3D bioprinted myocardium patches for rare Barth syndrome: TAZ mutation correction in cardioblasts
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 1096-1097
Open Access3D bioprinted myocardium patches for rare Barth syndrome: TAZ mutation correction in cardioblasts